While single-agent oncolytic virus therapy demonstrates meaningful clinical activity, combination with immune checkpoint inhibitors, adoptive cell therapy, and other immunomodulatory agents represents the strategic direction with greatest transformative potential. Checkpoint inhibitor combinations captured 18.4% of oncolytic virus market investment focus in 2025, as the ability of oncolytic viruses to convert immunologically "cold" tumors into "hot" T-cell-inflamed lesions addresses the primary resistance mechanism to anti-PD-1/PD-L1 therapy. T-VEC plus pembrolizumab in melanoma achieved 62% objective response rates, while multiple trials combining oncolytic viruses with nivolumab, atezolizumab, and durvalumab across tumor types were active. Over 34 oncolytic virus-checkpoint inhibitor combination trials were ongoing in 2025.

Adoptive cell therapy combinations are emerging, where oncolytic viruses create inflammatory tumor microenvironments that enhance tumor-infiltrating lymphocyte (TIL) therapy, CAR-T cell trafficking, and persistence. Oncolytic Virus Therapy Market analysis indicates that preclinical models demonstrate enhanced CAR-T efficacy when combined with oncolytic vaccinia or adenovirus expressing chemokines that recruit engineered T-cells to tumor sites. Over 8 oncolytic virus-CAR-T combination programs were in preclinical or early clinical development in 2025.

Mechanistically, oncolytic viruses achieve anti-tumor effects through multiple interconnected pathways: direct oncolysis of infected cancer cells releases damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) that activate innate immunity; immunogenic cell death exposes tumor antigens to dendritic cells; type I interferon responses enhance antigen presentation; and expressed transgenes (GM-CSF, IL-12, checkpoint inhibitors) modulate adaptive immunity. The abscopal effect, where local viral treatment induces systemic anti-tumor immunity against distant non-injected lesions, is the hallmark of successful oncolytic virus immunotherapy and the basis for combination strategies. Understanding and optimizing these mechanisms through biomarker development, immune monitoring, and rational combination design is essential for advancing the field. As mechanistic insights deepen and combination protocols standardize, oncolytic virus therapy is transitioning from local cytotoxic treatment to systemic immune platform that enhances the efficacy of diverse immunotherapy modalities.

Q1: How do oncolytic viruses enhance checkpoint inhibitor efficacy? Viruses convert cold tumors into hot T-cell-inflamed lesions; T-VEC plus pembrolizumab achieved 62% response rates in melanoma, with 34+ combination trials ongoing across tumor types in 2025.

Q2: What is the abscopal effect in oncolytic virus therapy? Local viral treatment induces systemic anti-tumor immunity against distant non-injected lesions through DAMP/PAMP release, antigen presentation, and adaptive immune activation— the hallmark of successful immunotherapy.

Q3: How do oncolytic viruses combine with CAR-T cell therapy? Viruses expressing chemokines enhance CAR-T trafficking and persistence; 8+ combination programs were in development in 2025, creating inflammatory microenvironments that support engineered T-cell function.